Tokyo Tape
Sign in
← Kirin Holdings

Half-year report · Q2

2503.TEDINET S100U68G
Period2024-01-01 → 2024-06-30
Filed2024-08-08
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥1.10T2024-01-01 → 2024-06-30Cons.Revenue IFRS
Revenue¥2.13T2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥970.2bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Operating income¥80.9bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Operating income¥36.9bn2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Profit before tax¥108.5bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Profit before tax¥197.0bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥57.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥57.2bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥112.7bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥32.0bn2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥74.2bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Net income¥41.8bn2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Total assets¥3.13Tat 2024-06-30Cons.Assets IFRS
Total assets¥2.87Tat 2023-12-31Cons.Assets IFRS
Total assets¥2.60Tat 2023-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥1.55Tat 2024-06-30Cons.Liabilities IFRS
Total liabilities¥1.44Tat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥1.59Tat 2024-06-30Cons.Equity IFRS
Net assets / equity¥1.43Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥1.33Tat 2023-06-30Cons.Equity IFRS
Net assets / equity¥1.25Tat 2022-12-31dCons.Equity IFRS
Equity (owners)¥1.29Tat 2024-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.13Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.06Tat 2023-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥138.4bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥131.4bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥140.0bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥88.1bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥108.7bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥203.2bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥58.9bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥116.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥226.1bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥56.0bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥21.6bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥35.9bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥15.6bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥70.652024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥139.162023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥39.52023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥70.652024-01-01 → 2024-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥139.152023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥39.492023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio41.2%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio39.5%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio40.8%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-01-01 → 2024-06-30¥45.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-01-01 → 2024-06-30¥10.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-01-01 → 2024-06-30¥34.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-01-01 → 2024-06-30−¥331m
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥38.5bn
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥38.5bn
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥26.5bn
jpcrp040300-q2r_E00395-000Alcoholic Beveragesreportable segmentrevenue2024-01-01 → 2024-06-30¥513.7bn
jpcrp040300-q2r_E00395-000Alcoholic Beveragesreportable segmentrevenue external2024-01-01 → 2024-06-30¥512.5bn
jpcrp040300-q2r_E00395-000Alcoholic Beveragesreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥1.2bn
jpcrp040300-q2r_E00395-000Alcoholic Beveragesreportable segmentsegment profit2024-01-01 → 2024-06-30¥50.3bn
jpcrp040300-q2r_E00395-000Health Sciencereportable segmentrevenue2024-01-01 → 2024-06-30¥71.1bn
jpcrp040300-q2r_E00395-000Health Sciencereportable segmentrevenue external2024-01-01 → 2024-06-30¥69.6bn
jpcrp040300-q2r_E00395-000Health Sciencereportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥1.6bn
jpcrp040300-q2r_E00395-000Health Sciencereportable segmentsegment profit2024-01-01 → 2024-06-30−¥1.6bn
jpcrp040300-q2r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue2024-01-01 → 2024-06-30¥271.5bn
jpcrp040300-q2r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue external2024-01-01 → 2024-06-30¥270.0bn
jpcrp040300-q2r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥1.5bn
jpcrp040300-q2r_E00395-000Non Alcoholic Beveragesreportable segmentsegment profit2024-01-01 → 2024-06-30¥30.1bn
jpcrp040300-q2r_E00395-000Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-06-30¥233.0bn
jpcrp040300-q2r_E00395-000Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-06-30¥232.8bn
jpcrp040300-q2r_E00395-000Pharmaceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥132m
jpcrp040300-q2r_E00395-000Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-06-30¥41.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-06-30¥44.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-06-30¥13.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-06-30¥31.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-06-30−¥435m
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥36.1bn
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥36.1bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥24.0bn
jpcrp040300-q2r_E00395-000Alcoholic Beveragesreportable segmentrevenue2023-01-01 → 2023-06-30¥482.0bn
jpcrp040300-q2r_E00395-000Alcoholic Beveragesreportable segmentrevenue external2023-01-01 → 2023-06-30¥480.9bn
jpcrp040300-q2r_E00395-000Alcoholic Beveragesreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥1.0bn
jpcrp040300-q2r_E00395-000Alcoholic Beveragesreportable segmentsegment profit2023-01-01 → 2023-06-30¥45.0bn
jpcrp040300-q2r_E00395-000Health Sciencereportable segmentrevenue2023-01-01 → 2023-06-30¥38.0bn
jpcrp040300-q2r_E00395-000Health Sciencereportable segmentrevenue external2023-01-01 → 2023-06-30¥36.2bn
jpcrp040300-q2r_E00395-000Health Sciencereportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥1.8bn
jpcrp040300-q2r_E00395-000Health Sciencereportable segmentsegment profit2023-01-01 → 2023-06-30−¥4.4bn
jpcrp040300-q2r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue2023-01-01 → 2023-06-30¥242.4bn
jpcrp040300-q2r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue external2023-01-01 → 2023-06-30¥241.0bn
jpcrp040300-q2r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥1.4bn
jpcrp040300-q2r_E00395-000Non Alcoholic Beveragesreportable segmentsegment profit2023-01-01 → 2023-06-30¥23.0bn
jpcrp040300-q2r_E00395-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-06-30¥199.2bn
jpcrp040300-q2r_E00395-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-06-30¥199.0bn
jpcrp040300-q2r_E00395-000Pharmaceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥210m
jpcrp040300-q2r_E00395-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-06-30¥36.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 831
ItemContextValueUnit
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E00395-000HealthScienceReportableSegmentMember36192000000JPY
Revenue from external customers IFRSPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember13107000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration970232000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00395-000AlcoholicBeveragesReportableSegmentMember1028000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00395-000NonAlcoholicBeveragesReportableSegmentMember1392000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00395-000PharmaceuticalsReportableSegmentMember210000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00395-000HealthScienceReportableSegmentMember1823000000JPY
Intersegment revenue IFRSPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember31602000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-36055000000JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00395-000AlcoholicBeveragesReportableSegmentMember481951000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00395-000NonAlcoholicBeveragesReportableSegmentMember242403000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00395-000PharmaceuticalsReportableSegmentMember199209000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00395-000HealthScienceReportableSegmentMember38015000000JPY
Revenue IFRSPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember44709000000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-36055000000JPY
Revenue IFRSPrior1YTDDuration970232000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E00395-000AlcoholicBeveragesReportableSegmentMember44955000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E00395-000NonAlcoholicBeveragesReportableSegmentMember22995000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E00395-000PharmaceuticalsReportableSegmentMember36119000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E00395-000HealthScienceReportableSegmentMember-4426000000JPY
Segment profit loss IFRSPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember-435000000JPY
Segment profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-24037000000JPY
Segment profit loss IFRSPrior1YTDDuration75171000000JPY
Other operating income IFRSPrior1YTDDuration4190000000JPY
Other operating expenses IFRSPrior1YTDDuration42439000000JPY
Finance income IFRSPrior1YTDDuration5767000000JPY
Finance costs IFRSPrior1YTDDuration2842000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration17228000000JPY
Profit loss before tax IFRSPrior1YTDDuration57074000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E00395-000AlcoholicBeveragesReportableSegmentMember512499000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E00395-000NonAlcoholicBeveragesReportableSegmentMember270044000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E00395-000PharmaceuticalsReportableSegmentMember232842000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E00395-000HealthScienceReportableSegmentMember69564000000JPY
Revenue from external customers IFRSCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember10874000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentYTDDuration1095823000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E00395-000AlcoholicBeveragesReportableSegmentMember1193000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E00395-000NonAlcoholicBeveragesReportableSegmentMember1471000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E00395-000PharmaceuticalsReportableSegmentMember132000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E00395-000HealthScienceReportableSegmentMember1571000000JPY
Intersegment revenue IFRSCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember34173000000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-38540000000JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E00395-000AlcoholicBeveragesReportableSegmentMember513692000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E00395-000NonAlcoholicBeveragesReportableSegmentMember271514000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E00395-000PharmaceuticalsReportableSegmentMember232974000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E00395-000HealthScienceReportableSegmentMember71135000000JPY
Revenue IFRSCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember45048000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass